Table 4.
Association between the severity of NAFLD at baseline and increasing levels of worsening of glycaemic control at follow-up in postmenopausal women with type 2 diabetes.
| Ordered Logistic Regression Models | Odds Ratios (95% CI) | p-Value |
|---|---|---|
| Unadjusted model | ||
| NAFLD and clinically significant fibrosis § | 6.16 (1.48–25.7) | 0.013 |
| Adjusted model 1 | ||
| NAFLD and clinically significant fibrosis | 6.15 (1.47–25.9) | 0.013 |
| Age (years) | 1.01 (0.95–1.08) | 0.733 |
| BMI (kg/m2) | 0.97 (0.87–1.06) | 0.462 |
| Adjusted model 2 | ||
| NAFLD and clinically significant fibrosis | 6.11 (1.46–26.6) | 0.014 |
| Age (years) | 1.01 (0.95–1.09) | 0.696 |
| BMI (kg/m2) | 0.96 (0.86–1.06) | 0.431 |
| GLP-1 receptor agonist use | 1.53 (0.28–8.21) | 0.621 |
| Adjusted model 3 | ||
| NAFLD and clinically significant fibrosis | 6.97 (1.62–30.0) | 0.009 |
| Age (years) | 0.99 (0.92–1.06) | 0.801 |
| BMI (kg/m2) | 0.96 (0.86–1.06) | 0.385 |
| SGLT-2 inhibitor use | 0.14 (0.01–1.69) | 0.123 |
| Adjusted model 4 | ||
| NAFLD and clinically significant fibrosis | 5.96 (1.42–25.1) | 0.015 |
| Age (years) | 1.01 (0.95–1.08) | 0.665 |
| BMI (kg/m2) | 0.96 (0.87–1.07) | 0.481 |
| Pioglitazone use | 1.25 (0.40–31.0) | 0.982 |
Sample size, n = 61. Data are expressed as odds ratio and 95% confidence intervals (CI) as tested by ordered logistic regression analyses. The presence of four increasing categories of worsening of glycaemic control at follow-up (i.e., arbitrarily defined as HbA1c increases ≤ 0.19%, from 0.20% to 0.49%, from 0.50% to 0.99% and ≥1%, respectively) was the ordinal dependent variable in all these models. All covariates included in these regression models were recorded at baseline. § Clinically significant fibrosis was defined by LSM ≥ 7 kPa on Fibroscan®.